PGC-1α
Inhibitory Selectivity
PGC-1α Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S8528 |
SR-18292SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α. |
||
| S1168 |
Valproic Acid (NSC 93819) sodium saltValproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. |
Western blot analysis of Acetylated Histone and Histone. 0-10μM sodium valproate was added.
|
|
| S3944 |
Valproic acid (VPA)Valproic acid (VPA, 2-Propylvaleric Acid, Sodium valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling. |
||
| S7447 |
ZLN005ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator. |
ZLN005 increased Sirt1 protein expression in cardiomyocytes.
|
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S8528 |
SR-18292SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1168 |
Valproic Acid (NSC 93819) sodium saltValproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. |
Western blot analysis of Acetylated Histone and Histone. 0-10μM sodium valproate was added.
|
|
| S3944 |
Valproic acid (VPA)Valproic acid (VPA, 2-Propylvaleric Acid, Sodium valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling. |
||
| S7447 |
ZLN005ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator. |
ZLN005 increased Sirt1 protein expression in cardiomyocytes.
|
